Enanta Pharmaceutica (ENTA)

$5.58 -0.09 (-1.59%)
Market Cap 119.04M
Revenue (ttm) 67.64M
Net Income (ttm) -116.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -171.57%
Debt to Equity Ratio 0.00
Volume 179,000
Avg Vol 341,688
Day's Range N/A - N/A
Shares Out 21.33M
Stochastic %K 86%
Beta 0.69
Analysts Sell
Price Target $15.14

Latest News on ENTA

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025

Apr 8, 2025, 7:00 AM EDT - 19 days ago

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025

Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 17, 2025, 7:00 AM EDT - 5 weeks ago

Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

Mar 12, 2025, 7:00 AM EDT - 6 weeks ago

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

Feb 10, 2025, 4:01 PM EST - 2 months ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 7:00 AM EST - 3 months ago

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

Dec 24, 2024, 7:00 AM EST - 4 months ago

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Dec 9, 2024, 6:30 AM EST - 4 months ago

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

Dec 6, 2024, 5:00 PM EST - 5 months ago

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024

Nov 25, 2024, 4:01 PM EST - 5 months ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

Sep 26, 2024, 6:00 AM EDT - 7 months ago

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals to Participate in Investor Conferences in September

Sep 3, 2024, 7:00 AM EDT - 8 months ago

Enanta Pharmaceuticals to Participate in Investor Conferences in September

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter

Aug 5, 2024, 4:01 PM EDT - 9 months ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter

Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference

May 29, 2024, 7:00 AM EDT - 11 months ago

Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference

Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference

May 7, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference

Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Transcript

May 6, 2024, 8:34 PM EDT - 1 year ago

Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Transcript

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET

May 6, 2024, 4:01 PM EDT - 1 year ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 30, 2024, 7:10 AM EDT - 1 year ago

Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

Apr 30, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

Apr 17, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference

Mar 6, 2024, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript

Feb 7, 2024, 10:04 PM EST - 1 year ago

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET

Feb 7, 2024, 4:01 PM EST - 1 year ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023

Jan 31, 2024, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Enanta: Multiple Shots On Goal For RSV Makes This A Must Watch

Nov 30, 2023, 3:34 PM EST - 1 year ago

Enanta: Multiple Shots On Goal For RSV Makes This A Must Watch

Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference

Nov 22, 2023, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference

Enanta Pharmaceuticals, Inc. (ENTA) Q4 2023 Earnings Call Transcript

Nov 20, 2023, 9:43 PM EST - 1 year ago

Enanta Pharmaceuticals, Inc. (ENTA) Q4 2023 Earnings Call Transcript

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET

Nov 20, 2023, 4:01 PM EST - 1 year ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023

Nov 13, 2023, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023

Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline

Oct 13, 2023, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline

Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference

Sep 17, 2023, 12:00 PM EDT - 1 year ago

Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference

Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023

Sep 7, 2023, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023

Enanta Pharmaceuticals, Inc. (ENTA) Q3 2023 Earnings Call Transcript

Aug 7, 2023, 8:42 PM EDT - 1 year ago

Enanta Pharmaceuticals, Inc. (ENTA) Q3 2023 Earnings Call Transcript

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET

Aug 7, 2023, 4:01 PM EDT - 1 year ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET

Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023

Jul 31, 2023, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023

Enanta Pharmaceuticals shares gain after RSV treatment shows positive results in early trial

Jun 20, 2023, 8:06 AM EDT - 2 years ago

Enanta Pharmaceuticals shares gain after RSV treatment shows positive results in early trial

Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus

Jun 20, 2023, 7:00 AM EDT - 2 years ago

Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus

Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023

Jun 7, 2023, 7:00 AM EDT - 2 years ago

Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023

Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference

May 31, 2023, 7:00 AM EDT - 2 years ago

Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference

Enanta Pharmaceuticals to Participate in Two Investor Conferences in May

May 9, 2023, 7:00 AM EDT - 2 years ago

Enanta Pharmaceuticals to Participate in Two Investor Conferences in May

Enanta Pharmaceuticals, Inc. (ENTA) Q2 2023 Earnings Call Transcript

May 8, 2023, 6:48 PM EDT - 2 years ago

Enanta Pharmaceuticals, Inc. (ENTA) Q2 2023 Earnings Call Transcript

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET

May 8, 2023, 4:01 PM EDT - 2 years ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET

Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19

May 8, 2023, 4:01 PM EDT - 2 years ago

Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19

Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023

May 2, 2023, 4:01 PM EDT - 2 years ago

Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023

Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million

Apr 25, 2023, 8:01 AM EDT - 2 years ago

Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million

Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

Apr 17, 2023, 7:00 AM EDT - 2 years ago

Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus

Apr 6, 2023, 7:00 AM EDT - 2 years ago

Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus